Table 1.

The correlation between PRMT5 expression and the clinicopathological features in EAC.

Clinicopathological feature	Number of patients	PRMT5 expression (score)			P value
		0	1–4	5–12
Age (years)					0.206
≤45	10	1	4	5
>45	32	1	8	23
Myometrial invasion					0.897
<1/2	28	0	10	18
≥1/2	14	2	2	10
Cervical involvement					1.000
Uninvolved	37	2	10	25
Involved	5	0	2	3
Lymph node metastasis					0.093
−	39	1	11	27
+	3	1	1	1
Adnexal metastasis					1.000
−	36	2	10	24
+	6	0	2	4
ER (score)					0.007*
0–4	18	2	8	8
5–12	24	0	4	20
PR (score)					0.136
0–4	11	0	6	5
5–12	31	2	6	23
p53					0.941
Wild type (≥1 and <30%)	38	2	11	25
Wild type (≥30 and <70%)	4	0	1	3
Ki‐67					0.015*
≤30%	19	2	8	9
>30%	23	0	4	19
Grade					0.016*
G1	21	0	4	17	1.000 †
G2	14	0	4	10	0.017 ‡
G3	7	2	4	1	0.054 §
FIGO stage					0.762
I	32	1	9	22
II	3	0	1	2
III	7	1	2	4
IV	0	0	0	0

The expression of PRMT5 in G1, G2, and G3 EAC was compared in pairs.

^* P < 0.05.

^† G1 versus G2.

^‡ G2 versus G3.

^§ G1 versus G3.